Sanne A E Peters
Overview
Explore the profile of Sanne A E Peters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
166
Citations
5367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moreno Velasquez I, Peters S, Dragano N, Greiser K, Dorr M, Fischer B, et al.
J Am Heart Assoc
. 2025 Feb;
14(5):e038708.
PMID: 39996451
Background: Using data from the largest German cohort study, we aimed to investigate sex differences in the relationship of socioeconomic position (SEP) with cardiovascular disease (CVD), CVD risk factors, and...
2.
de Vries S, Pena M, Tye S, Peters S, van Raalte D, Arnott C, et al.
Diabetologia
. 2024 Dec;
68(3):507-515.
PMID: 39656268
Aims/hypothesis: Our aim was to assess sex differences in the efficacy of angiotensin receptor blockers (i.e. losartan and irbesartan) on kidney and cardiovascular outcomes in individuals with type 2 diabetes...
3.
4.
Peters S, Rodgers A, Patel A, Norton R, Huffman M, Agarwal A
Eur J Prev Cardiol
. 2024 Sep;
PMID: 39303054
Background: The polypill is an emerging strategy for the prevention and management of cardiovascular disease. We assessed the participation of females in randomised controlled trials evaluating polypills for prevention of...
5.
Satheesh G, Dhurjati R, Alston L, Tesfay F, Pant R, Bahiru E, et al.
Glob Heart
. 2024 Sep;
19(1):74.
PMID: 39281002
Optimal use of guideline-directed medical therapy (GDMT) can prevent hospitalization and mortality among patients with heart failure (HF). We aimed to assess the prevalence of GDMT use for HF across...
6.
Ojo A, Ojji D, Grobbee D, Huffman M, Peters S
Glob Heart
. 2024 Jun;
19(1):50.
PMID: 38863890
Background: Globally, cardiovascular disease (CVD) remains the leading cause of mortality and disability, with hypertension being the single most important modifiable risk factor. Hypertension is responsible for about 18% of...
7.
Helmink M, Peters S, Westerink J, Harris K, Tillmann T, Woodward M, et al.
Eur J Prev Cardiol
. 2024 Apr;
31(14):1671-1678.
PMID: 38584392
Aims: Identifying patients with established cardiovascular disease (CVD) who are at high risk of type 2 diabetes (T2D) may allow for early interventions, reducing the development of T2D and associated...
8.
Kiss P, Uijl A, de Boer A, Duk T, Grobbee D, Hollander M, et al.
Heart
. 2024 Apr;
110(15):981-987.
PMID: 38580433
Background: Current guidelines for the prevention and management of cardiovascular diseases (CVD) provide similar recommendations for the use of statins in both women and men. In this study, we assessed...
9.
Rissanen I, Basten M, Exalto L, Peters S, Visseren F, Geerlings M
J Neurol
. 2024 Mar;
271(6):3347-3358.
PMID: 38493278
Background And Purpose: Risk factors for stroke differ between women and men in general populations. However, little is known about sex differences in secondary prevention. We investigated if sex interacted...
10.
Helmink M, Hageman S, Eliasson B, Sattar N, Visseren F, Dorresteijn J, et al.
Diabetes Obes Metab
. 2024 Mar;
26(6):2229-2238.
PMID: 38456579
Aims: To develop and externally validate the LIFE-T1D model for the estimation of lifetime and 10-year risk of cardiovascular disease (CVD) in individuals with type 1 diabetes. Materials And Methods:...